The Impact of Perioperative Immunosuppression on Post-surgical Outcomes in Patients with Inflammatory Bowel Disease
Nicholas P Valle1, Andrew R Roney2, Shaya Noorian3
1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. nicholasvalle@mednet.ucla.edu.
Purpose:
Patients with inflammatory bowel disease (IBD) often require immunosuppression and abdominal surgery for medication-refractory disease. We evaluated whether perioperative biologic/advanced therapies, corticosteroids, and immunomodulators were associated with postoperative complications after IBD-related abdominal surgery.
Methods:
This retrospective cohort included adults with chart-confirmed IBD undergoing index IBD-related abdominal surgery at a tertiary center from January 2010 to January 2024. Demographic, disease, surgical, medication, and outcome variables were abstracted. Biologic/advanced therapy exposure was defined as treatment within 8 weeks preoperatively and/or 4 weeks postoperatively, and corticosteroid and immunomodulator exposure were defined within 4 weeks before and/or after surgery. Outcomes included 30-day infection, sepsis, reoperation, readmission, and length of stay (LOS). Multivariable models adjusted for demographic, disease, surgical, and concomitant medication variables when available.
Results:
Among 274 patients, 181 (66%) received perioperative biologic/advanced therapy, 129 (47%) corticosteroids, and 94 (34%) immunomodulators. Biologic/advanced therapy was not associated with increased composite 30-day postoperative complications. Composite complications occurred in 37/127 (29.1%) patients receiving anti-TNFs, 5/21 (23.8%) receiving anti-integrins, and 3/13 (23.1%) receiving IL-12/23 or IL-23 inhibitors. Immunomodulators were associated with intra-abdominal infection (OR 3.6, 95% CI 1.1-12.0) and urinary tract infection (OR 4.3 95% CI 1.2-15.9), while corticosteroids were associated with sepsis (OR 11.3, 95% CI 1.2-109.8). Postoperative biologic/advanced therapy exposure was associated with shorter postoperative LOS (- 1.5 days).
Conclusions:
Perioperative biologic/advanced therapy exposure was not associated with increased 30-day postoperative complications, supporting continuation when clinically indicated. Corticosteroid and immunomodulator associations with infectious complications support steroid minimization, judicious immunomodulator use, and medication-class-specific perioperative risk assessment in multidisciplinary IBD surgical care.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:26Inflammatory Bowel Disease I: Introduction
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...